MA5-15124

antibody from Invitrogen Antibodies

Targeting: SMAD5 Dwfc, JV5-1, MADH5

Western blot (Supportive data in Antibodypedia)

Immunocytochemistry (Supportive data in Antibodypedia)

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-15124

Provider

Invitrogen Antibodies

Product name

Phospho-SMAD1/SMAD5 (Ser463, Ser465) Monoclonal Antibody (E.239.4)

Antibody type

Monoclonal

Antigen

Synthetic peptide

Description

It is not recommended to aliquot this antibody.

Antibody clone number

E.239.4

Concentration

148 µg/mL

References

Submitted references

Gukang Capsule Promotes Fracture Healing by Activating BMP/SMAD and Wnt/β-Catenin Signaling Pathways.

Ma X, Yang J, Liu T, Li J, Lan Y, Wang Y, Wang A, Tian Y, Li Y
Evidence-based complementary and alternative medicine : eCAM 2020;2020:7184502

---

Bone morphogenetic protein 7 promotes resistance to immunotherapy.

Cortez MA, Masrorpour F, Ivan C, Zhang J, Younes AI, Lu Y, Estecio MR, Barsoumian HB, Menon H, Caetano MDS, Ramapriyan R, Schoenhals JE, Wang X, Skoulidis F, Wasley MD, Calin G, Hwu P, Welsh JW
Nature communications 2020 Sep 24;11(1):4840

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of Phospho-Smad1/5 pSer463/465 in extracts from untreated or BMP-4-treated HeLa cells using Phospho-Smad1/5 pSer463/465 monoclonal antibody (Product # MA5-15124).

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent analysis of Phospho-Smad1/5 pSer463/465 in HT-1080 cells, BMP-treated, using a Phospho-Smad1/5 pSer463/465 monoclonal antibody (Product # MA5-15124) (green). Actin filaments are labeled with a fluorescent red phalloidin.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent analysis of Phospho-Smad1/5 pSer463/465 in HT-1080 cells using a Phospho-Smad1/5 pSer463/465 monoclonal antibody (Product # MA5-15124) (green). Actin filaments are labeled with a fluorescent red phalloidin.

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometric analysis of Phospho-Smad1/5 pSer463/465 in untreated (blue) or BMP-treated (green) HeLa cells using a Phospho-Smad1/5 pSer463/465 monoclonal antibody (Product # MA5-15124) compared to a nonspecific negative control antibody (red).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 5 GKC activates the BMP/Smad signaling pathway, promoting osteogenic differentiation of SaOS-2 cells. (a) Western blot showing the levels of phosphorylated Smad1/5, Smad1/5, and Smad4 after 24 h of treatment with GKC at different concentrations ( n = 3). (b) BMP2 and RUNX2 protein expression were downregulated in SaOS-2 cells treated with 1.5 mu g/mL Noggin for 5 h ( n = 3). (c) ALP staining (7 days) and Alizarin red staining (14 days) of SaOS-2 cells showed that Noggin treatment reverses the effects of GKC on ALP activity and the formation of mineralized nodules ( n = 3). * P < 0.05, relative to the control group. # P < 0.01, relative to the GKC treatment groups.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 2 BMP7 modulates MAPK14 in anti-PD1-resistant tumors and immune cells. a Reverse phase protein array (RPPA) results on expression levels and activation status of 243 proteins in 344SQP ( n = 3 biologically independent samples) and 344SQR ( n = 3 biologically independent samples) tumors treated with anti-PD1(10 mg/kg). Normalized data were first log2-transformed (log2(x + 1)). Proteins expressed at different levels between groups (downregulated proteins in green and upregulated proteins in red) were identified by a P value of